Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2018-07
-
br Conclusions There are a number of factors that affect
2021-12-14

Conclusions There are a number of factors that affect the transit of solutes through gap junction channels. Fig. 4 provides a simplified illustration of those factors. First is the cytoplasmic vestibule through which all permeable solutes must pass to gain access to the pore. In an equivalent cir
-
br Gamma secretase trafficking GS activity for
2021-12-14

Gamma-secretase trafficking GS activity for APP can be influenced by sub-cellular trafficking, as APP cleavage differs depending on its localization. APP is synthesized in the ER and transported to the trans-Golgi network (Annaert et al., 1999, Pasternak et al., 2003, Ray et al., 1999a, Rechards
-
A way to identify what subunit interfaces contribute to
2021-12-14

A way to identify what subunit interfaces contribute to the pharmacology of agents is to utilise binary GABAARs as tool receptors to ascertain possible binding sites for particular ligands. These receptors can help identify subunits and subunit interfaces that contribute to receptor pharmacology. In
-
br The potential of EPA Ffar
2021-12-14

The potential of EPA-Ffar4 signaling as a novel intervention for HFpEF Conclusions and future directions Optimization of ω3-PUFA/EPA-therapy based upon titration to achieve therapeutic levels: A pressing clinical challenge is to continue to define the benefit of ω3-PUFA/EPA-therapy. Recent ana
-
In non Hodgkin lymphoma the catalytic SET domain
2021-12-13

In non-Hodgkin lymphoma the catalytic SET domain of the histone methyltransferase EZH2 is subject to recurrent heterozygous missense mutations . These alterations have been observed in ∼20% of patients with diffuse large B cell lymphoma (DLBCL) and ∼10% of patients with follicular lymphoma (FL). The
-
The third group also included samples belonging to subjects
2021-12-13

The third group also included samples belonging to subjects with undetectable viraemia, for which the negative or persistence of the indeterminate WB result in subsequent samples indicated a non-HIV infection. In this subgroup, the VITROS HIV Combo test (as well as the other two tests) was negative
-
A second site of histone
2021-12-13

A second site of histone core domain acetylation that that has been observed on newly synthesized histones is histone H4 lysine 91 [34]. H4 lysine 91 lies along the interface between the H3/H4 tetramer and the H2A/H2B dimers. In fact, H4 lysine 91 normally forms a salt bridge with an aspartic ski or
-
The repurposing of well characterized and well tolerated dru
2021-12-13

The repurposing of well-characterized and well-tolerated drugs in order to treat illnesses for which they were not originally intended has emerged as an attractive alternative to a long and costly process of drug development. Repositioning antihistaminergic ligands seems a promising idea given that
-
The relaxant response to carperitide was influenced neither
2021-12-13

The relaxant response to carperitide was influenced neither by the removal of the endothelium nor by treatment with the nitric oxide synthase inhibitor or nitric oxide scavenger. This result was to be expected as previous studies showing that the vasodilator action of atrial natriuretic peptide is e
-
In parallel we were also
2021-12-13

In parallel, we were also preparing and evaluating other piperidine bioisosteres and modifications to – to further access additional novel intellectual property (IP) space. Modeling work suggested that 4-position homologated piperidines, as well as 3-position homologated azetidines overlapped favora
-
br Material and methods br
2021-12-13

Material and methods Results Discussion Neurosteroids capable of blocking the NMDAR channel attract a lot of attention as possible therapeutic agents for the treatment of neurodegenerative diseases. A large number of new nmda antagonist with different structures have been synthesized in or
-
carnitine palmitoyltransferase The effects of GHS R a blocka
2021-12-13

The effects of GHS-R1a blockade on alcohol-related outcomes have been examined in numerous preclinical experiments, utilizing various GHS-R1a antagonists (JMV 2959, [D-Lys3]-GHRP-6, BIM 28163) and rodent species (prairie vole, mouse, rat). In spite of methodological differences, the results consiste
-
In addition we assessed the
2021-12-13

In addition, we assessed the viability of 1,2,3,4-tetrahydroquinoline (13t) and 1,2,3,4-tetrahydroisoquinoline (13u) as the tail on account of our previous SAR results. To our delight, 13t and 13u each had comparable activity to that of 13c, with 13u being slightly more potent than 13c. Further stru
-
br Introduction For decades regulated apoptosis and unregula
2021-12-13

Introduction For decades, regulated apoptosis and unregulated, accidental necrosis have been considered as the two sole cell death routes in multicellular organisms. With the beginning of the 21st century a paradigm shift has been witnessed by researchers in the field with the recognition that ma
-
Nilvadipine In the past two decades studies of the
2021-12-13

In the past two decades, studies of the non-B cell-derived Ig, including cancer cell-derived IgG, have been predominately facilitated by general anti-human Ig antibodies, which do not distinguish the non-B Ig from classical Ig derived from B cells. Due to this caveat, it remains obscure about whethe
14470 records 517/965 page Previous Next First page 上5页 516517518519520 下5页 Last page